KRAS and lung carcinoma: For instance, PTEN is rarely mutated in KRAS- and BRAF-driven human lung cancers, and yet Pten inactivation provides a very strong tumor fitness advantage in our autochthonous mouse models (Fig. 6B and Supplementary Fig. 11A, B).